Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline: European Commission Authorizes Nimenix

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 02:24pm CET

GlaxoSmithKline PLC (>> GlaxoSmithKline plc), the drug company, said Friday that the European Commission has granted marketing authorization for Nimenrix, Meningococcal group A, C, W-135 and Y conjugate vaccine, for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.

-Shares at 1207 GMT, up a penny, or 0.04%, at 1,420.5 pence valuing the company at GBP71.61 billion.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; [email protected]

Stocks mentioned in the article : GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
08:08a GLAXOSMITHKLINE : GSK submit IMPACT data to support Trelegy Ellipta
08:01a GLAXOSMITHKLINE : GSK Submits Landmark IMPACT Data to US Regulatory Authority to..
11/22 GLAXOSMITHKLINE PLC : (GSK) Shares Bought by Comerica Bank
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
11/22 GLAXOSMITHKLINE : ViiV Juluca approved in US as first 2-drug regimen
11/21 GLAXOSMITHKLINE : Findings on Biomimetics Reported by Investigators at GlaxoSmit..
11/21 GLAXOSMITHKLINE : Data on Sulfonamides Detailed by Researchers at GlaxoSmithKlin..
11/21 GLAXOSMITHKLINE : Findings from GlaxoSmithKline plc in the Area of Colitis Repor..
11/21 GLAXOSMITHKLINE : GSK publishes 2018 dividend dates
11/21 Brexit gets real for drugmakers as regulator moves to Amsterdam
More news
News from SeekingAlpha
11/22 GILEAD : Buying New Growth
11/22 YOUR DAILY PHARMA SCOOP : Teva Valuation, DelMar Lead Candidate, Galapagos Comme..
11/21 'Safer' Dividend Follower Favorites Leader Is Spark Energy, As Per November G..
11/21 Followers Find Frontier Tops By Broker Target Gains & Yield For November
11/21 FDA OKs ViiV Healthcare's two-drug combo for HIV-1
Financials ( GBP)
Sales 2017 30 089 M
EBIT 2017 8 449 M
Net income 2017 3 716 M
Debt 2017 14 279 M
Yield 2017 6,14%
P/E ratio 2017 18,24
P/E ratio 2018 14,74
EV / Sales 2017 2,60x
EV / Sales 2018 2,56x
Capitalization 64 066 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 15,7  GBP
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-16.61%85 349
JOHNSON & JOHNSON19.78%371 653
NOVARTIS11.20%220 090
ROCHE HOLDING LTD.-1.55%212 522
PFIZER8.90%211 844
MERCK AND COMPANY-6.23%148 014